公开(公告)号：US20240358670A1

公开(公告)日：2024-10-31

申请号：US18766386

申请日：2024-07-08

Applicant: Viotika Life Sciences Inc.

Inventor： Pavel Dibrov ,  Elena Dibrov ,  Grant Pierce

IPC: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655

CPC classification number: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655 ,  C07F9/65515 ,  A61K2300/00 ,  Y02A50/30

Abstract: An antibiotic compound of formula (I):




or a salt or stereoisomer thereof; wherein R1-R3 and R5-R6 are independently selected from H or a C1-C5 alkyl group or a C1-C5 substituted alkyl group; R4 is a C1-C5 alkyl group or a C1-C5 substituted alkyl group; X1-X2 are independently selected from the group consisting of ═O, H, and OH; Y is an acyclic hydrocarbon chain of 2 to 20 carbon atoms; and Z is CH3. Also disclosed are methods of treating a bacterial disease including administering an effective amount of the compound to a subject in need thereof, wherein the bacterial disease is caused by a gram-negative bacteria.

公开(公告)号：US12029716B2

公开(公告)日：2024-07-09

申请号：US17660886

申请日：2022-04-27

Applicant: Viotika Life Sciences Inc.

Inventor： Pavel Dibrov ,  Elena Dibrov ,  Grant Pierce

IPC: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655

CPC classification number: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655 ,  C07F9/65515 ,  A61K2300/00 ,  Y02A50/30

Abstract: An antibiotic compound of formula (I):




or a salt or stereoisomer thereof; wherein: R1-R3 and R5-R6 are independently selected from H or a C1-C5 alkyl group or a C1-C5 substituted alkyl group; R4 is a C1-C5 alkyl group or a C1-C5 substituted alkyl group; X1-X2 are independently selected from the group consisting of ═O, H, and OH; Y is an acyclic hydrocarbon chain having 2 to 20 carbon atoms or a substituted acyclic hydrocarbon chain having 2 to 20 carbon atoms; and Z is a neutral or positively charged organic group including a nitrogen or phosphorus atom, the nitrogen or phosphorous atom forming a covalent bond with a carbon atom of Y. Also disclosed are methods of treating a bacterial disease including administering an effective amount of the compound to a subject in need thereof, wherein the bacterial disease is caused by a gram-negative bacteria.

公开(公告)号：US11987563B1

公开(公告)日：2024-05-21

申请号：US18371110

申请日：2023-09-21

Applicant: KING FAISAL UNIVERSITY

Inventor： Katharigatta N. Venugopala ,  Pran Kishore Deb ,  Raghu Prasad Mailavaram

IPC: C07D307/68 ,  A61K31/341 ,  A61P31/04 ,  A61P31/06 ,  C07D307/66

CPC classification number: C07D307/68 ,  A61K31/341 ,  A61P31/04 ,  A61P31/06 ,  C07D307/66

Abstract: Compounds for treating a microbial infection and/or tuberculosis and, particularly, antimicrobial and/or antitubercular compounds that are 3-cyano 4,5-diphenyl furan-2-carboxamides and their use as antimicrobial and/or antitubercular agents are provided.

公开(公告)号：US11897857B2

公开(公告)日：2024-02-13

申请号：US17119602

申请日：2020-12-11

Applicant: Midwestern University

Inventor： Mark Jon Olsen ,  Jean Paul Seerden

IPC: C07D307/66 ,  A61P35/04

CPC classification number: C07D307/66 ,  A61P35/04 ,  C07B2200/05

Abstract: Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) β-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.

公开(公告)号：US20230028660A1

公开(公告)日：2023-01-26

申请号：US17899297

申请日：2022-08-30

Applicant: The University of Sydney

Inventor： Michael KASSIOU ,  William JORGENSEN ,  Lenka MUNOZ

IPC: C07D213/75 ,  C07D213/82 ,  C07D241/24 ,  C07D307/66 ,  C07D317/66

Abstract: The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

公开(公告)号：US20220220101A1

公开(公告)日：2022-07-14

申请号：US17710386

申请日：2022-03-31

Applicant: Ottawa Hospital Research Institute ,  University of Ottawa

Inventor： Jean-Simon Diallo ,  Christopher Noyce Boddy ,  Mark Dornan ,  Ramya Krishnan ,  Rozanne Arulanandam ,  Fabrice Le Boeuf ,  Jeffrey Smith ,  Andrew Macklin

IPC: C07D413/06 ,  C07D237/14 ,  C07D207/38 ,  C07D307/60 ,  C07D307/66 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D307/30 ,  C07D307/58 ,  C07D405/06 ,  A61K45/06 ,  A61K31/501 ,  C12N7/00 ,  C07D207/36 ,  C07D207/456 ,  C07D317/64 ,  C07D417/06 ,  C07D471/04 ,  A61P35/02 ,  C07D209/48 ,  C07D231/08

Abstract: Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

公开(公告)号：US11261378B2

公开(公告)日：2022-03-01

申请号：US15539666

申请日：2015-12-17

Applicant: DIC CORPORATION

Inventor： Masahiro Horiguchi ,  Sayaka Nose ,  Akihiro Koiso

IPC: C09K19/54 ,  C07C69/753 ,  C07C69/76 ,  C07D333/22 ,  C07D339/06 ,  C07D339/08 ,  C07D407/12 ,  C07D409/12 ,  C07C323/21 ,  C07D413/12 ,  C07D417/04 ,  C07D417/06 ,  C07D249/06 ,  C07C327/48 ,  C07C251/24 ,  C07D207/452 ,  C07C251/86 ,  C07C251/88 ,  C07D209/12 ,  C07D277/82 ,  C07D513/04 ,  C08F20/10 ,  G02B5/30 ,  C07C69/94 ,  C07C69/75 ,  C09K19/34 ,  C07D409/14 ,  C07D305/06 ,  C07C251/78 ,  C07D403/04 ,  C07D209/40 ,  C07D303/48 ,  C09K19/32 ,  C07D495/04 ,  C07C69/757 ,  C07C245/08 ,  C07D333/36 ,  C07D307/66 ,  C07D403/12 ,  C07D417/12 ,  C07D265/16 ,  C07D249/04 ,  C07D213/74 ,  C07C251/18 ,  C07D409/06 ,  C07D333/76 ,  C07D277/64 ,  C07D209/88 ,  C09K19/38 ,  G02F1/13363 ,  C09K19/04 ,  C08F220/30

Abstract: The present invention aims to provide a polymerizable compound that has high storage stability without causing crystal precipitation when added to a polymerizable composition and to provide a polymerizable composition containing the polymerizable compound. A polymer film produced by polymerization of the polymerizable composition has a low haze, high thickness uniformity, low occurrence of nonuniform orientation, high surface hardness, high adhesiveness, and good appearances and fewer orientation defects even after ultraviolet irradiation. The present invention also aims to provide a polymer produced by polymerization of the polymerizable composition and an optically anisotropic body produced from the polymer.

公开(公告)号：US20210171439A1

公开(公告)日：2021-06-10

申请号：US16771387

申请日：2018-12-10

Applicant: VenatoRx Pharmaceuticals, Inc.

Inventor： Christopher J. BURNS ,  Glen COBURN ,  Bin LIU ,  Jiangchao YAO ,  Christopher BENETATOS ,  Steven A. Boyd ,  Stephen M. CONDON

IPC: C07C233/64 ,  A61K45/06 ,  C07D211/46 ,  C07D307/66 ,  C07D265/30 ,  C07D309/14

Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

公开(公告)号：US20200262804A1

公开(公告)日：2020-08-20

申请号：US16791252

申请日：2020-02-14

Applicant: Midwestern University

Inventor： Mark Jon Olsen ,  Jean Paul Seerden

IPC: C07D307/66 ,  A61P35/04

Abstract: Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) β-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.

公开(公告)号：US10259804B2

公开(公告)日：2019-04-16

申请号：US15514157

申请日：2015-09-23

Applicant: Shifa Biomedical Corporation

Inventor： Nabil Elshourbagy ,  Shaker Mousa ,  Harold Meyers

IPC: C07D405/12 ,  C07D405/14 ,  C07D307/66

Abstract: Endothelial Lipase (EL) inhibitors and methods of using such inhibitors for treating conditions implicating EL are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of EL function that can be used therapeutically to raise HDL cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including, but not limited to, familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, and, more generally, cardiovascular disease (CVD).